#USA #Boston #financial results #SOPHiA GENETICS #AI Precision Medicine

SOPHiA GENETICS Reports Preliminary Financial Performance for Q4 and Full Year 2025

SOPHiA GENETICS, a leader in AI-powered precision medicine, has released its preliminary unaudited financial results for the fourth quarter and full year of 2025. Alongside this, the company forecasts revenue growth for 2026 and details a significant management transition. The announcements were made on January 12, 2026, from the company’s headquarters in Boston and Rolle, Switzerland.

Financial Highlights for Q4 2025

The company closed out 2025 with impressive financial results:

• - Revenue: Estimated to be at least $21 million, reflecting an approximate 20% increase year-over-year.
• - Analyses Conducted: Over 105,000 analyses were performed using SOPHiA DDM™, marking a 16% growth compared to the previous year.

These results indicate that SOPHiA GENETICS has not only met but exceeded expectations for growth in a competitive sector.

Overview of Full Year 2025 Results

For the entirety of 2025, SOPHiA GENETICS reported:

• - Total Revenue: Approximately $77 million, representing an 18% increase over the prior year.
• - Analyses Conducted: A record-breaking total of over 391,000 analyses utilized SOPHiA DDM™, underlining the platform's growing acceptance in the healthcare industry.

Jurgi Camblong, CEO of SOPHiA GENETICS, stated, "2025 was an exceptionally successful year for SOPHiA GENETICS as we accelerated our revenue growth and significantly exceeded our new business entry targets. Our strong performance positions us well for continued success in 2026 and beyond with our leading product offerings and a reviving biopharma business."

Forward-Looking Statements for 2026

Looking ahead, SOPHiA GENETICS has set optimistic projections for 2026:

• - Annual Revenue Growth: Expected to be between $92 million and $94 million, equating to a growth rate of 20 to 22% over the previous year.
• - Adjusted EBITDA Loss: Anticipated to be between $29 million to $32 million.

These estimates reflect the company’s commitment to enhancing its operational strengths and market positioning.

Leadership Transition Announced

A noteworthy aspect of the announcements includes the planned transition of leadership:

• - Ross Muken is slated to become CEO starting July 1, 2026. Muken has been a crucial part of SOPHiA GENETICS since joining as CFO before the company went public in 2021. Over the years, his contributions have been integral to reshaping the sales organization and driving business growth.
• - Jurgi Camblong, the current CEO and co-founder, will transition to the role of Executive Chairman, focusing on strategic initiatives and the long-term vision of the company.

Dr. Tomer Berkovitz expressed confidence in these leadership changes, emphasizing the strong foundation that Jurgi has built over the years. “These changes reflect the board’s long-term succession planning,” he said, highlighting the company's vision for ongoing innovation in precision medicine.

Continued Commitment to Innovation

As SOPHiA GENETICS gears up for 2026, it highlights its commitment to harnessing technology for improved patient care. The company’s platforms aim to democratize access to data-driven medicine, and with applications like MSK-ACCESS® combined with SOPHiA DDM™, they are in a strong position to capitalize on market opportunities in the United States and beyond.

“Having worked closely with Ross, I am confident that he is the right person to lead our next phase of growth and to significantly expand our global footprint,” commented Jurgi Camblong.

In conclusion, SOPHiA GENETICS is poised for a promising future as it transitions into a new chapter with fresh leadership and innovative offerings in the field of precision medicine. Investors and stakeholders can anticipate the full financial results for Q4 2025 and further insights during the upcoming earnings call scheduled for March 3, 2026. Stay tuned for more updates from one of the frontrunners in healthcare technology.